抗血小板药物研究进展

被引：19

作者：

杨宏艳

王晓良

机构：

[1] 中国医学科学院-北京协和医学院药物研究所

来源：

中国药学杂志 | 2012年 / 47卷 / 04期

关键词：

血小板; 血栓; 抗血小板药物; 血栓素; 凝血酶;

D O I：

暂无

中图分类号：

R973 [血液和造血系统药物];

学科分类号：

1007 ;

摘要：

目的综述抗血小板药物的应用现状和研究进展。方法在总结国内外文献的基础上,对临床上现有的抗血小板药物以及正在研究中的新的抗血小板药物及其新靶标进行总结和分析。结果与结论抗血小板药物开发是一个热门的研究领域,当前对血小板生物学以及对血小板黏附、活化和聚集相关的机制以及药物作用的潜在靶点有了越来越多的了解,笔者主要从影响血小板黏附、活化扩增,抑制血小板聚集及抗血小板作用新靶点等方面进行综述,并对未来开发出具有临床作用的新靶点的抗血小板药物,为血栓栓塞性疾病提供安全、有效的药物治疗进行展望。

引用

页码：250 / 254

页数：5

共 13 条

[1] Modulation of Vasoactivity and Platelet Aggregation by Selective 5-HT Receptor Antagonism in Humans [J].

Moerland, Matthijs ;

Kemme, Michiel ;

Dijkmans, Anneke ;

Bergougnan, Luc ;

Burggraaf, Jacobus .

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2011, 58 (06) :575-580

[2] Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects [J].

Kosoglou, Teddy ;

Reyderman, Larisa ;

Tiessen, Renger G. ;

van Vliet, Andre A. ;

Fales, Robert R. ;

Keller, Robert ;

Yang, Bo ;

Cutler, David L. .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 68 (03) :249-258

[3]

Position of tirofiban in ST segment elevation myocardial infarction treatment: more than an adjunctive therapy[J] . Blood Coagulation & Fibrinolysis . 2011 (5)

[4]

The novel and orally active thrombin receptor antagonist E5555 (Atopaxar) inhibits arterial thrombosis without affecting bleeding time in guinea pigs[J] . Motoji Kogushi,Toshiyuki Matsuoka,Tsutomu Kawata,Hiroko Kuramochi,Shinki Kawaguchi,Kimiyo Murakami,Hironobu Hiyoshi,Shuichi Suzuki,Tetsuya Kawahara,Akiharu Kajiwara,Ieharu Hishinuma.European Journal of Pharmacology . 2011 (1)

[5]

Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors During Elective Coronary Revascularization[J] . David E. Winchester,Xuerong Wen,William D. Brearley,Ki E. Park,R. David Anderson,Anthony A. Bavry.Journal of the American College of Cardiology . 2011 (10)

[6]

Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial[J] . Yukito Shinohara,Yasuo Katayama,Shinichiro Uchiyama,Takenori Yamaguchi,Shunnosuke Handa,Kempei Matsuoka,Yasuo Ohashi,Norio Tanahashi,Hiroko Yamamoto,Chokoh Genka,Yasuhisa Kitagawa,Hideo Kusuoka,Katsuya Nishimaru,Motoo Tsushima,Yukihiro Koretsune,Tohru Sawada,Chikuma Hamada.Lancet Neurology . 2010 (10)

[7] Antiplatelet and antithrombotic activities of salvianolic acid A [J].

Fan, Hua-Ying ;

Fu, Feng-Hua ;

Yang, Ming-Yan ;

Xu, Hui ;

Zhang, Ai-Hong ;

Liu, Ke .

THROMBOSIS RESEARCH, 2010, 126 (01) :E17-E22

[8]

Curcumin inhibits GPVI-mediated platelet activation by interfering with the kinase activity of Syk and the subsequent activation of PLC&ggr;2[J] . Azad Mayanglambam,Carol A. Dangelmaier,Dafydd Thomas,C. Damodar Reddy,James L. Daniel,Satya P. Kunapuli.Platelets . 2010 (3)

[9]

Addition of cilostazol reduces biological aspirin resistance in aspirin users with ischaemic stroke: a double‐blind randomized clinical trial[J] . J.‐H.Lee,J.‐K.Cha,S. J.Lee,S.‐W.Ha,S. U.Kwon.European Journal of Neurology . 2010 (3)

[10]

Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A Randomized, Double-Blind, Aspirin-Controlled Trial[J] . Yukito Shinohara,Katsuya Nishimaru,Tohru Sawada,Akiro Terashi,Shunnosuke Handa,Shunsaku Hirai,Kunihiko Hayashi,Hideo Tohgi,Yasuo Fukuuchi,Shinichiro Uchiyama,Takenori Yamaguchi,Shotai Kobayashi,Kazuoki Kondo,Eiichi Otomo,Fumio Gotoh.Stroke . 2008 (6)

← 1 2 →